At pre-symptomatic stage, treatment of ALS mice with CD4+ T lymphocytes significantly delays the onset of symptoms (action ascribed to CD4+ CD25+regulatory T-cells) and increases the latency between disease onset and entry into late stage (action mediated by CD4+ CD25−effector cells) [66, 67]. Here, CD4 is linked to amyotrophic lateral sclerosis.